References
- GreenbergPLAttarEBennettJMNational Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromesJ Natl Compr Canc Netw201191305621233243
- SekeresMASchoonenWMKantarjianHCharacteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveysJ Natl Cancer Inst2008100211542155118957672
- SantiniVAlessandrinoPEAngelucciEItalian Society of HematologyClinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelinesLeuk Res201034121576158820149927
- RitchieEKLachsMSManagement of myelodysplastic syndromes in the geriatric patientCurr Hematol Malig Rep2009413920425432
- RitchieEKSafety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeClin Interv Aging2012716517322791989
- GreenbergPLCoslerLEFerroSALymanGHThe costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network GuidelinesJ Natl Compr Canc Netw20086994295318926103
- NiscolaPTendasAGiovanniniMTransfusions at home in patients with myelodysplastic syndromesLeuk Res201236668468822336393
- TendasANiscolaPAlesMDisability and physical rehabilitation in patients with advanced haematological malignancies followed in a home care programSupport Care Cancer200917121559156019701814
- HartiganIA comparative review of the Katz ADL and the Barthel Index in assessing the activities of daily living of older peopleInt J Older People Nurs20072320421220925877
- GreenbergPCoxCLeBeauMMInternational scoring system for evaluating prognosis in myelodysplastic syndromesBlood1997896207920889058730
- MalcovatiLGermingUKuendgenATime-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesJ Clin Oncol200725233503351017687155
- Della PortaMGMalcovatiLStruppCRisk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndromeHaematologica201196344144921134982
- LyonsRMCosgriffTMModiSSHematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromesJ Clin Oncol200927111850185619255328
- Garcia-ManeroGMyelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and managementAm J Hematol201287769270122696212
- SeymourJFFenauxPSilvermanLREffects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromesCrit Rev Oncol Hematol201076321822720451404
- FenauxPMuftiGJHellström-LindbergEAzacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaJ Clin Oncol201028456256920026804
- FenauxPMuftiGJHellstrom-LindbergEInternational Vidaza High-Risk MDS Survival Study GroupEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol200910322323219230772
- SilvermanLRDemakosEPPetersonBLRandomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BJ Clin Oncol200220102429244012011120
- GurionRVidalLGafter-GviliA5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome — a systematic review and meta-analysisHaematologica201095230331019773261
- KornblithABHerndonJE2ndSilvermanLRImpact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B studyJ Clin Oncol200220102441245212011121
- NiscolaPde FabritiisPCartoniCHome care management of patients affected by hematologic malignancies: a reviewHaematologica200691111523152917082010
- BrunettiGATendasAMeloniEPain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignanciesAnn Hematol201190101233123521287348